1. SOLID-TIMI 52
Trial design: Participants within 30 days of an acute coronary syndrome (ACS) were randomized to darapladib 160 mg daily (n = 6,504) versus placebo (n = 6,522).
(p = 0.93)
Results
CHD death, MI, or urgent coronary revascularization for myocardial ischemia at 2.5 years: 16.3% of the darapladib group vs. 15.6% of the placebo group (p = 0.93)
CHD death: 3.8% vs. 4.2% (p = 0.16), respectively
MI: 10.3% vs. 10.2% (p = 0.63), respectively
Urgent coronary revascularization: 4.2% vs. 3.6% (p = 0.36), respectively
16.3
15.6 %
Conclusions
Among patients with recent ACS, darapladib was not associated with a reduction in adverse cardiovascular events compared with placebo
Darapladib
Placebo
O’Donoghue ML, et al. JAMA 2014;312: